Reviewing Nexeon Medsystems (OTCMKTS:NXNN) and Nexalin Technology (NASDAQ:NXL)

Nexalin Technology (NASDAQ:NXL) and Nexeon Medsystems (OTCMKTS:NXNN) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Risk and Volatility

Nexalin Technology has a beta of 4.2, meaning that its share price is 320% more volatile than the S&P 500. Comparatively, Nexeon Medsystems has a beta of 6.98, meaning that its share price is 598% more volatile than the S&P 500.

Earnings and Valuation

This table compares Nexalin Technology and Nexeon Medsystems”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$162,078.00	293.86	-$4.65 million	($0.64)	-5.59
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A

Nexeon Medsystems has lower revenue, but higher earnings than Nexalin Technology.

Analyst Recommendations

This is a summary of current ratings for Nexalin Technology and Nexeon Medsystems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	1	0	0	2.00
Nexeon Medsystems	0	0	0	0	0.00

Nexalin Technology currently has a consensus target price of $3.00, indicating a potential downside of 16.20%. Given Nexeon Medsystems’ higher probable upside, analysts clearly believe Nexeon Medsystems is more favorable than Nexalin Technology.

Insider and Institutional Ownership

0.6% of Nexalin Technology shares are held by institutional investors. 24.0% of Nexalin Technology shares are held by insiders. Comparatively, 61.2% of Nexeon Medsystems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Nexalin Technology and Nexeon Medsystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,407.98%	-187.59%	-167.21%
Nexeon Medsystems	N/A	N/A	N/A

Summary

Nexeon Medsystems beats Nexalin Technology on 6 of the 9 factors compared between the two stocks.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.